Develops drugs for multiple myeloma and non-small-cell lung cancer.
Jun 2026Revenue $35.0M/yrExpenses $147M/yr
No trendCash runway ≈ 11 months from Jun 2026
Figures by year
When will C4 Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $35.0M and expenses $147M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $35.9M | $151M | −$115M |
| Dec 2024 | $35.6M | $155M | −$120M |
| Dec 2023 | $20.8M | $160M | −$139M |
| Dec 2022 | $31.1M | $161M | −$130M |
| Dec 2021 | $45.8M | $128M | −$82.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.